Trial · NCT07885592
Neonatal Outcomes on Direct Fetal Intravenous Immunoglobulin During Intrauterine Transfusion for Rhesus Isoimmunization
NCT07885592, Phase 2, Recruiting, Post Graduate Institute of Medical Education and Research, Chandigarh
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neonatal Outcomes on Direct Fetal Intravenous Immunoglobulin During Intrauterine Transfusion for Rhesus Isoimmunization. Trials, record NCT07885592. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07885592
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neonatal Outcomes on Direct Fetal Intravenous Immunoglobulin During Intrauterine Transfusion for Rhesus Isoimmunization
- NCT number
- NCT07885592
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Conditions
- Hemolytic Disease of the Newborn, Fetal Anemia, Rhesus Isoimmunization, Erythroblastosis Fetalis Due to RH Antibodies
- Interventions
- Intrauterine Transfusion, Intravenous immunoglobulin (IVIG)
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cord Blood Hematocrit at Birth | At birth (Day 1) | Hematocrit measured from umbilical cord venous blood immediately after delivery, expressed as percentage of red blood cell volume. |
| Secondary | Rate of Post-Transfusion Decline in Fetal Hematocrit | From first intrauterine transfusion until delivery | Change in fetal hematocrit per day following intrauterine transfusion, calculated between procedures. |
| Secondary | Need for Phototherapy | From birth until 28 days or discharge, whichever is earlier | Proportion of neonates requiring phototherapy for management of hyperbilirubinemia. |
| Secondary | Duration of Phototherapy | From birth until 28 days or discharge, whichever is earlier | Total duration of phototherapy administered to the neonate, measured in hours. |
| Secondary | Need for Exchange Transfusion | From birth until 28 days or discharge, whichever is earlier | Proportion of neonates requiring double-volume exchange transfusion. |
| Secondary | Number of Postnatal Packed Red Blood Cell Transfusions | From birth until 28 days or discharge, whichever is earlier | Number of packed red blood cell transfusions administered to the neonate. |
| Secondary | Procedure-Related Adverse Events | Periprocedural to upto 1 week after IUT | Occurrence of complications related to intrauterine transfusion or fetal intravenous immunoglobulin administration. This includes fetal bradycardia requiring intervention, cord bleeding or hematoma, procedure-related fetal loss, preterm labor, maternal fever or suspected infection, and any acute hemodynamic instability following fetal intravenous immunoglobulin administration. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 23941890 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07885592
GET https://conductscience.org/api/trials/v1/NCT07885592/registered